Catalog No.
DHC90711
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11836
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
hA20 / IMMU-106, CAS: 728917-18-8
Clone ID
Veltuzumab
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects, PMID: 20214444
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience, PMID: 28983798
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121
Treatment Update of Autoimmune Blistering Diseases, PMID: 30850044
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris, PMID: 25133328
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody, PMID: 18941114
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study, PMID: 23829485
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma, PMID: 21173095
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results, PMID: 19451441
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia, PMID: 27515248
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia, PMID: 26389849
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma, PMID: 19223402
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma, PMID: 25847298
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma, PMID: 25150258
Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura, PMID: 19330725
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab), PMID: 18829494
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line, PMID: 24386925
Rituximab resistance, PMID: 21658619
Bullous Diseases, PMID: 29131038
Future therapies for pemphigus vulgaris: Rituximab and beyond, PMID: 26792592
Novel agents for chronic lymphocytic leukemia, PMID: 23680477
Emerging immunological drugs for chronic lymphocytic leukemia, PMID: 26153226
B-cell depletion in immune thrombocytopenia, PMID: 23664523
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies, PMID: 21090841
CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas, PMID: 19710501
Novel CD20 monoclonal antibodies for lymphoma therapy, PMID: 23057966
Shifting Focus in the Therapeutics of Immunobullous Disease, PMID: 28584371
CD20-targeted therapy: the next generation of antibodies, PMID: 20350667
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias, PMID: 20628151
[Novel B-cell directed strategies for the treatment of rheumatic diseases], PMID: 19513729
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era, PMID: 28499646
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment, PMID: 29143151
Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development, PMID: 21105187
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art, PMID: 25249370
The future of CD20 monoclonal antibody therapy in B-cell malignancies, PMID: 20367564
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus, PMID: 24841238
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma, PMID: 20425465
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies, PMID: 22039078
Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics, PMID: 18922911
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties, PMID: 23116517
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas, PMID: 22271448
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action, PMID: 18025153
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma, PMID: 19372261
Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides, PMID: 20127947
Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia, PMID: 19562616
Hepatocyte paraffin 1 immunoexpression in esophageal brush samples, PMID: 15918175
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells, PMID: 20876805
Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody, PMID: 15815716
Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus, PMID: 20534646
Interferon-λ1 linked to a stabilized dimer of Fab potently enhances both antitumor and antiviral activities in targeted cells, PMID: 23696859
For research use only. Not for human or drug use.
